Genocea Announces Positive Top-Line Phase 1 Results for Novel Universal Pneumococcus Vaccine Candidate GEN-004. Brennan CaruthersJune 23, 2014
F-star achieves milestone in collaboration with Boehringer Ingelheim. Brennan CaruthersJanuary 9, 2014
Genocea Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering. Brennan CaruthersDecember 23, 2013
Covagen and Tanabe Research Laboratories Expand Strategic Research Collaboration for Development of Bispecific FynomAbs. Brennan CaruthersDecember 6, 2013
Genocea Biosciences Initiates Phase 1 Study of Vaccine Candidate Gen-004 to Prevent Infections Caused by Pneumococcus. Brennan CaruthersDecember 5, 2013
F-star announces formation of new asset-centric vehicle, F-star Alpha Ltd, with €9.4m Series A investment. Brennan CaruthersOctober 23, 2013
Pronota Is To Receive Patent On Biomarker For Diagnosing Renal Failure In The US Despite Prometheus. Brennan CaruthersJune 6, 2013
International Consortium Awarded 6 Million Euro To Validate Pre-Eclampsia Early Detection Tests. Brennan CaruthersNovember 5, 2012
Genkyotex's NOX Inhibitor GKT137831 Phase I Data Presented at Kidney Week 2012. Brennan CaruthersNovember 2, 2012
Thrasos Secures $35 Million to Fund THR-184 Phase 2 Clinical Program for Treatment of Acute Kidney Injury. Brennan CaruthersOctober 25, 2012
Covagen enters into a strategic research collaboration and license agreement with Mitsubishi Tanabe for the development of bispecific FynomAbs. Brennan CaruthersOctober 17, 2012
Genocea Closes $30 Million in Series C Financing. The Bill & Melinda Gates Foundation and CVF join as new investors. Brennan CaruthersOctober 10, 2012
Genocea Initiates a Phase 1/2a Study with its Therapeutic Vaccine Candidate for Herpes Simplex Virus-2 (HSV-2). Brennan CaruthersAugust 15, 2012
Pronota's Risk Stratification Test Breaks New Ground in the Early Detection of Pre-term Pre-eclampsia. Brennan CaruthersJuly 9, 2012
Genkyotex Announces Successful Phase Ia Data with First in Class NOX Inhibitor GKT137831. Brennan CaruthersJune 22, 2012
Pronota Strengthens Management Team Former VP Corporate Development Genzyme joins as CBO. Brennan CaruthersMarch 16, 2012
Shire to acquire FerroKin BioSciences, Inc., and its Phase 2 iron chelator treatment. Brennan CaruthersMarch 15, 2012
Pronota announces EUR 3.7 million Series C financing ; management and board changes. Brennan CaruthersJanuary 20, 2012
